Cell therapy (CAR-T) · Kills target cells, directed at ROR1
PRGN-3007 is an autologous T-cell therapy engineered with a non-viral transposon to express an anti-ROR1 chimeric antigen receptor, membrane-bound IL-15, a kill switch and intrinsic PD-1 downregulation. The CAR directs the T cells to ROR1-expressing tumor cells for lysis. It is studied in chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05694364 | Phase 1 | Chronic Lymphocytic Leukemia | Completed | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaMantle Cell LymphomaTriple Negative Breast Cancer Malignancies